<DOC>
	<DOCNO>NCT00003439</DOCNO>
	<brief_summary>Phase I trial study effectiveness interleukin-12 treating patient refractory ovarian abdominal cancer . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With Refractory Advanced-Stage Ovarian Cancer Abdominal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess safety maximum tolerate dose recombinant human interleukin-12 ( rhIL-12 ) administer intraperitoneal infusion patient chemotherapy refractory advanced ovarian cancer diffuse abdominal carcinomatosis . II . Determine immunopharmacologic profile rhIL-12 patient population . III . Evaluate biologic response select patient rhIL-12 administered intraperitoneal infusion . OUTLINE : This dose escalation , multicenter study . Cohorts 3-6 patient receive escalate dos intraperitoneal recombinant human interleukin-12 ( rhIL-12 ) administer weekly 9 week . If patient tolerate rhIL-12 show evidence objective response stable disease , patient may receive 9 additional week treatment . Treatment continue absence unacceptable toxicity disease progression . Dose escalation continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 6 patient experience dose limit toxicity . All patient follow survival .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm intraabdominal cancer Diffuse abdominal carcinomatosis Chemotherapy refractory advance stage ovarian cancer Measurable disease Residual , recurrent , metastatic disease beyond scope standard curative therapy Extension disease sit distant peritoneal cavity allow Retroperitoneal lymphadenopathy allow long evaluable intraabdominal disease No history progressive brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Hemoglobin great 9 g/dL WBC great 3,000/mm3 Platelet count great 100,000/mm3 Bilirubin less 2.0 mg/dL ALT le 100 U/L Creatinine clearance great 60 mL/min Normal electrocardiogram No recent history cardiac ischemia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Hepatitis B negative No evidence clinical immunodeficiency syndrome immunodeficiency associate diseases No history autoimmune disease No concurrent major illness No serious infection require intravenous antibiotic No active peptic ulcer disease Must free flow fluid peritoneal space No leakage catheter exit site PRIOR CONCURRENT THERAPY : At least 3 week since prior biologic therapy ( 6 week interleukin2 ) No prior recombinant human interleukin12 At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) No concurrent systemic chemotherapy No concurrent systemic corticosteroid No prior radiation therapy whole abdomen No concurrent radiotherapy At least 3 week since prior exposure investigational drug No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>